KRAS and cancer: However, groundbreaking progress has been made with the FDA approval of KRAS G12C inhibitors such as Sotorasib (AMG510) (Skoulidis et al., 2021) and Adagrasib (MRTX849) (Jänne et al., 2022), marking a significant milestone in cancer therapy.